Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
26 hedge funds and large institutions have $11M invested in Marinus Pharmaceuticals, Inc in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
2% less capital invested
Capital invested by funds: $11.3M → $11M (-$277K)
7% less funds holding
Funds holding: 28 → 26 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$600K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$287K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$152K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$139K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$97.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPV
Canaan Partners VII
Westport,
Connecticut
|
-$3.13M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$695K |
| 3 |
O
OrbiMed
New York
|
-$507K |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$381K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$115K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CPV
26
Canaan Partners VII
Westport,
Connecticut
| – | -$3.13M | -615,350 | Closed |
|
|
JGC
27
J. Goldman & Co
New York
| – | -$695K | -136,823 | Closed |
|
|
PI
28
Putnam Investments
Boston,
Massachusetts
| – | -$381K | -75,000 | Closed |
|
|
DCM
29
DAFNA Capital Management
Los Angeles,
California
| – | -$115K | -22,559 | Closed |
|
|
BA
30
BlackRock Advisors
Wilmington,
Delaware
| – | -$41K | -8,007 | Closed |
|
31
Bank of New York Mellon
New York
| – | -$21K | -4,119 | Closed |
|
32
Goldman Sachs
New York
| – | -$16K | -3,104 | Closed |
|
|
WS
33
Wedbush Securities
Los Angeles,
California
| – | -$14K | -2,750 | Closed |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| – | -$10K | -2,065 | Closed |
|
|
TCM
35
Tradewinds Capital Management
Bellingham,
Washington
| – | -$8K | -1,500 | Closed |
|
36
Wells Fargo
San Francisco,
California
| – | -$1K | -125 | Closed |
|
MRNS Hedge Fund Activity: Q3 2016 in Review
26 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2016, worth a combined $11M — down 2.5% from $11.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MRNS and 9 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $600K. The largest seller was Canaan Partners VII, exiting entirely with an estimated $3.13M sold.
- 26 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2016, down from 28 in Q2 2016.
- Funds reported $11M of Marinus Pharmaceuticals, Inc stock for Q3 2016, down 2.5% quarter-over-quarter.
- 9 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2016 and 11 closed out, a net change of -2 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2016 was ArrowMark Colorado Holdings, an estimated $600K added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2016 was Canaan Partners VII, an estimated $3.13M sold.
Based on aggregated 13F filings for Q3 2016.